Kodiak Sciences Inc. (KOD) Form 8-K — Aug 13, 2026
Kodiak Sciences reported a second-quarter 2026 net loss of $65.6 million, or $1.05 per share, wider than the $54.3 million, or $1.03 per share, loss a year ago, as R&D expenses rose 31% to $56.1 million on expanded Phase 3 clinical and manufacturing activity. The company ended the quarter with $125.9 million of cash, down from $209.9 million at year-end 2025, and said current cash supports planned operations into 2027 — a runway that implies a capital raise is likely before its late-stage programs reach the market.
Key figures
- Guidance
- Current cash and cash equivalents expected to support current and planned operations into 2027
- Total Assets
- 256811000
- Cash Position
- 125903000
- Ga Expense Q2
- 10755000
- Rnd Expense Q2
- 56083000
- Cash Dec312025
- 209862000
- Working Capital
- 78588000
- Alto Study Patients
- 910
- Anti VEGFMarket Size
- $15 billion
- Stockholders Equity
- 61096000
- Peak First Cohort Patients
- 300
- Weighted Avg Shares Q22025
- 52779162
- Weighted Avg Shares Q22026
- 62628596
- Stock Based Compensation Q2
- 11600000
Price after filing
Close on the filing date to close N calendar days later (from $39.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.